{"id":10580,"date":"2010-09-21T08:18:05","date_gmt":"2010-09-21T12:18:05","guid":{"rendered":"http:\/\/asweetlife.org\/?p=10580"},"modified":"2015-12-29T08:53:10","modified_gmt":"2015-12-29T13:53:10","slug":"novo-nordisks-new-ultra-long-acting-insulin-shows-lower-day-to-day-variability-compared-to-lantus","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=10580","title":{"rendered":"Novo Nordisk&#8217;s Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong><\/strong><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/09\/NovoNordiskLogo1.png\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-10581 lazyload\" style=\"margin: 4px;\" title=\"NovoNordiskLogo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/09\/NovoNordiskLogo1.png\" alt=\"\" width=\"172\" height=\"128\" \/><\/a>Novo Nordisk presented clinical pharmacology data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data demonstrate up to four times lower day-to-day variability in the total metabolic effect compared to insulin glargine (Lantus) in people with type 1 diabetes.\u00a0 The data were presented at the 46th Scientific Sessions of the European Association for the Study of Diabetes (EASD).<br \/> Additionally, Novo Nordisk presented phase 2 data which demonstrate insulin degludec\u2019s potential to achieve glycemic control when used once-daily or three times weekly in people with type 2 diabetes.<\/p>\n<p>For the full press release click here.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk presented clinical pharmacology data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data demonstrate up to four times lower day-to-day variability in the total metabolic effect compared to insulin glargine (Lantus) in people with type 1 diabetes.  The data were presented at the 46th Scientific Sessions of the European Association for the Study of Diabetes (EASD)&#8230;<\/p>\n","protected":false},"author":131,"featured_media":10581,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[143,1257],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novo Nordisk&#039;s Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus<\/title>\n<meta name=\"description\" content=\"Novo Nordisk presented data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data showed up to four times lower day-to-day variability in the total metabolic effect compared to Lantus in people with type 1 diabetes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=10580\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=10580\",\"url\":\"https:\/\/asweetlife.org\/?p=10580\",\"name\":\"Novo Nordisk's Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=10580#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=10580#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/09\/NovoNordiskLogo1.png\",\"datePublished\":\"2010-09-21T12:18:05+00:00\",\"dateModified\":\"2015-12-29T13:53:10+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Novo Nordisk presented data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data showed up to four times lower day-to-day variability in the total metabolic effect compared to Lantus in people with type 1 diabetes.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=10580#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=10580\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=10580#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/09\/NovoNordiskLogo1.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/09\/NovoNordiskLogo1.png\",\"width\":215,\"height\":160,\"caption\":\"Novo Nordisk Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=10580#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk&#8217;s Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk's Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus","description":"Novo Nordisk presented data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data showed up to four times lower day-to-day variability in the total metabolic effect compared to Lantus in people with type 1 diabetes.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=10580","twitter_misc":{"Written by":"ASweetLife Team"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=10580","url":"https:\/\/asweetlife.org\/?p=10580","name":"Novo Nordisk's Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=10580#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=10580#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/09\/NovoNordiskLogo1.png","datePublished":"2010-09-21T12:18:05+00:00","dateModified":"2015-12-29T13:53:10+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Novo Nordisk presented data for insulin degludec, an ultra-long-acting basal insulin currently under clinical investigation. The data showed up to four times lower day-to-day variability in the total metabolic effect compared to Lantus in people with type 1 diabetes.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=10580#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=10580"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=10580#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/09\/NovoNordiskLogo1.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/09\/NovoNordiskLogo1.png","width":215,"height":160,"caption":"Novo Nordisk Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=10580#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk&#8217;s Ultra- Long- Acting Insulin Shows Lower Day-to-Day Variability Compared to Lantus"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/10580"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10580"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/10580\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/10581"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10580"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10580"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10580"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}